Timberlyne Therapeutics vs Regeneron
Side-by-side comparison of AI visibility scores, market position, and capabilities
Raised $180M Series A (Jan 2025). CM313 achieved 95% response rate in treatment-refractory ITP in NEJM-published data. Multi-indication 2026 pipeline. CD38 target with differentiated cytotoxicity.
About
Timberlyne Therapeutics launched in January 2025 with $180 million in Series A financing from Abingworth, Bain Capital Life Sciences, and Venrock, developing CM313 — an anti-CD38 monoclonal antibody with differentiated complement-dependent cytotoxicity properties. CM313 achieved a 95% response rate in treatment-refractory immune thrombocytopenia (ITP) in data published in the New England Journal of Medicine in 2025 — a 95% response rate in refractory patients is exceptional in autoimmune disease.
Tarrytown NY biopharma giant; creator of Dupixent (>$14B revenue), Eylea, and Kevzara. Velocity Genome platform drives fast antibody and bispecific drug discovery.
About
Regeneron Pharmaceuticals was founded in 1988 in Tarrytown, New York by Leonard Schleifer and George Yancopoulos. The company built its reputation on the Velocimmune platform—a proprietary humanized mouse technology that dramatically accelerates the discovery of human antibodies—and has used it to produce multiple best-in-class biologics across inflammatory, oncologic, and eye diseases.\n\nRegeneron's commercial portfolio is anchored by Dupixent (dupilumab), developed with Sanofi, which has become one of the best-selling drugs globally with over $14 billion in 2024 revenues, treating atopic dermatitis, asthma, COPD, and other type-2 inflammatory conditions. Additional key products include Eylea (aflibercept) for macular degeneration and PRALUENT for cardiovascular cholesterol lowering. The company's bispecific antibody pipeline, cancer vaccines in collaboration with BioNTech, and gene therapy programs represent its next growth wave.\n\nRegeneron reported over $14 billion in annual revenue in 2024 and maintains a world-class science culture, consistently ranking among the top companies for R&D productivity and employee satisfaction. Its Tarrytown campus houses more than 10,000 employees and remains a leading independent US biopharmaceutical innovator.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Capabilities
Integrations
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.